147 related articles for article (PubMed ID: 9523171)
21. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
[TBL] [Abstract][Full Text] [Related]
22. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Komers R; Cooper ME
Am J Physiol; 1995 Apr; 268(4 Pt 2):F588-94. PubMed ID: 7733315
[TBL] [Abstract][Full Text] [Related]
23. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
24. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Fabris B; Candido R; Armini L; Fischetti F; Calci M; Bardelli M; Fazio M; Campanacci L; Carretta R
J Hypertens; 1999 Dec; 17(12 Pt 2):1925-31. PubMed ID: 10703891
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette RA; Mayer G; Park SK; Meyer TW
J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
[TBL] [Abstract][Full Text] [Related]
26. [Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Zhang DY; Yang YL; Chen WD; Huang YY; Li LH; Wang YW; Zhu XJ; Xu HH; Yang LC
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Dec; 19(12):762-3. PubMed ID: 18093443
[No Abstract] [Full Text] [Related]
27. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
28. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
29. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
30. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
Ding SS; Qiu C; Hess P; Xi JF; Zheng N; Clozel M
J Cardiovasc Pharmacol; 2003 Jul; 42(1):48-54. PubMed ID: 12827026
[TBL] [Abstract][Full Text] [Related]
31. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
32. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors in the prevention of experimental diabetic glomerulopathy.
Myers BD; Meyer TW
Am J Kidney Dis; 1989 Jan; 13(1):20-4. PubMed ID: 2643307
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic implications of converting-enzyme inhibitors in renal disease.
Anderson S; Brenner BM
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):81-7. PubMed ID: 3037894
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action.
Norman JT; Stidwill R; Singer M; Fine LG
Nephron Physiol; 2003; 94(2):p39-46. PubMed ID: 12845221
[TBL] [Abstract][Full Text] [Related]
36. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Motawi TK; El-Maraghy SA; Senousy MA
J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Ribeiro AB; Gavras H
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):327-33. PubMed ID: 16767299
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
[TBL] [Abstract][Full Text] [Related]
40. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
